РОССИЙСКАЯ АКАДЕМИЯ НАУК

УРАЛЬСКОЕ ОТДЕЛЕНИЕ

ИНСТИТУТ ХИМИИ TBEPДОГО ТЕЛА
   
| | | | |
| | | |
 30.08.2007   Карта сайта     Language По-русски По-английски
Новые материалы
Экология
Электротехника и обработка материалов
Медицина
Статистика публикаци


30.08.2007


Austrian NANO Initiative


„National cooperative Research and Technological Development in Cluster projects”



1



NANO-HEALTH



Nano-structured Materials for Drug Targeting, Release and Imaging



Objectives



The joint research project Nano-Health, which consists up to now of thirteen single projects,


aims to develop a platform of new multifunctional nanoparticles. These multifunctional


nanoparticles will be employed for:



 the non-invasive targeted delivery of active substances for the treatment of chronical


diseases by different application routes, e.g. nasal, oral and pulmonary.



 nanodiagnostics as contrast media in clinical imaging via magnetic resonance imaging


(MRI), via fluorescence and via nuclear imaging by PET/SPECT.



 nanodiagnostics for clinical applications for the early detection of atherosclerotic


vascular lesions and to trace stem cells in cancer treatment



 toxicological studies of nanostructured materials



Project description



The ageing population, the high expectations for better quality of life and the changing


lifestyle of the European society call for an improved, more efficient and affordable health


care. Cardiovascular problems, diabetes, cancer, inflammatory and infectious diseases are


severe illnesses to be dealt with. Nanotechnology applied to medical problems can offer


impressive solutions. Early diagnosis, imaging and ‘smart’ treatments by using nanoparticles


potentiate better personalized health care. The benefit of nanoparticles for early diagnosis,


imaging and as highly potent drug delivery systems is generally accepted. The Nano-Health


project consists of 13 research projects aiming to develop new generations of nanoparticles


for diagnosis, imaging and drug delivery. These new, multifunctional nanoparticles will be


employed for clinical relevant and severe illnesses, such as diabetes, cancer, pulmonary


arterial hypertension (PAH) and atherosclerosis . Nano-Health pursuits three major goals: i)


the development of a nanoparticle toolbox consisting of new, multifunctional nanoparticles


based on four different technologies; ii) the optimization and use of the best suitable


nanoparticles for early diagnosis and imaging of different applications like cancer,


atherosclerotic plaque, and stem cell monitoring; iii) optimization and use of the best suitable


nanoparticles for non-invasive drug delivery to the lung in the case of PAH, via oral


administration to the mucosa of the gut in the case of diabetes and osteoporosis, and via


nasal administration in the case of dwarfism.


The development of multifunctional nanoparticles in this RPC focuses on four different types


of nanoparticles. These nanoparticles are lipid based (LIPO-NP), protamine based


(Proticles), poly lactid acid – human serum albumin (PLA-HSA) based and thiomer based


(Thiomers). Each of theses technologies is the main research field of independent academic


partners of the research consortium. In the case of diagnosis and imaging, three different


visualization strategies by using magnetic resonance (MRI), fluorescence and radioactivity


are followed. Coupling of these tags allows the in vitro characterisation as well as in vivo


tracing of the different nanoparticles developed within the Consortium. In the case of drug


delivery, the pulmonary, oral and nasal delivery routes are envisaged. The focus in this


context is the “Injectable-to-non-invasive-conversion”.


Nanotoxicology is one important aspect of nanoparticles and nanotechnology in general.


Nanotoxicology will be particularly emphasized in the single research project Nano-Tox


which deals with toxicological aspects of nanostructured materials. Within this project,


numerous in vitro models will be established and used for the evaluation of possible toxicity


of the used nanoparticles within the consortium. This project closely collaborates with the


integrated EU project [Nano(Biopharmaceuticals], 6 RP. All four Austrian partners in this EU


project are also partners of Nano-Health and the EU project was stimulated by the design of


Nano-Health!


In order to reach our goals, the collaboration of numerous scientific disciplines is needed.


Close cooperation between industry, research centres, academia, hospitals, funding



Austrian NANO Initiative


„National cooperative Research and Technological Development in Cluster projects”



2


agencies, and other stakeholders is a key factor of success. Therefore, all medical


universities of Austria, three Austrian universities, two non-university research organisations


and three Small and Medium size Enterprise (SME) as well as one global player (Siemens


Medical Solutions) ally to build the joint research project Nano-Health.



Number of RTD projects in the cluster: 13 projects



Recent funding period: March 2005 – February 2009



Overall planned duration: Until 2011



Project volume: EUR 4.129.055,-



Funding: EUR 3.532.927,- (funding rate: 85,6%)



Project partner



- Institute of Medical Technologies and Health Management Joanneum Research


Forschungs GmbH; - Clinical Department of Nuclear Medicine, Innsbruck Medical Univ.;


Center for Medical Research, Medical University of Graz; - Clinical Institute of Medical and


Chemical Laboratory Diagnostics Medical University of Graz; - Department of Anatomy,


Histology & Embryology, Section of Histology & Embryology, Medical University of Innsbruck;


- Department of Chemistry, University of Vienna; - Department of Internal Medicine, Division


of Haematology, Medical University of Graz; - Department of Pharmaceutical Technology,


Univ. of Innsbruck; - Institute of Biophysics and Nanosystems Research, Austrian Academy


of Science; - Institute of Cancer Research, Univ. of Vienna Institute of Pharmaceutical


Chemistry & Pharmaceutical Technology, Univ. of Graz; - piCHEM Research&Development;


- Siemens Medical Solutions; - ThioMatrix Forschungs- und Beratungs GmbH



Project coordinator:



Dr. Frank Sinner, Elisabethstraße 9 – 11, 8010 Graz; JOANNEUM RESEARCH und


BioNanoNet Forschungsgesellschaft mbH; frank.sinner@joanneum.at und



frank.sinner@bionanonet.at, Tel.: +43-316-876-2111, www.bionanonet.at



Дизайн и программирование N-Studio 
А Б В Г Д Е Ё Ж З И Й К Л М Н О П Р С Т У Ф Х Ц Ч Ш Щ Ъ Ы Ь Э Ю Я
  • Chen Wev .  honorary member of ISSC science council

  • Harton Vladislav Vadim  honorary member of ISSC science council

  • Lichtenstain Alexandr Iosif  honorary member of ISSC science council

  • Novikov Dimirtii Leonid  honorary member of ISSC science council

  • Yakushev Mikhail Vasilii  honorary member of ISSC science council

  • © 2004-2019 ИХТТ УрО РАН
    беременность, мода, красота, здоровье, диеты, женский журнал, здоровье детей, здоровье ребенка, красота и здоровье, жизнь и здоровье, секреты красоты, воспитание ребенка рождение ребенка,пол ребенка,воспитание ребенка,ребенок дошкольного возраста, дети дошкольного возраста,грудной ребенок,обучение ребенка,родить ребенка,загадки для детей,здоровье ребенка,зачатие ребенка,второй ребенок,определение пола ребенка,будущий ребенок медицина, клиники и больницы, болезни, врач, лечение, доктор, наркология, спид, вич, алкоголизм православные знакомства, православный сайт творчeства, православные рассказы, плохие мысли, православные психологи рождение ребенка,пол ребенка,воспитание ребенка,ребенок дошкольного возраста, дети дошкольного возраста,грудной ребенок,обучение ребенка,родить ребенка,загадки для детей,здоровье ребенка,зачатие ребенка,второй ребенок,определение пола ребенка,будущий ребенок